Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2024 14:30 ET | Source: Custom Market Insights

[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Austin, TX, USA, March 28, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “PARP Inhibitors Market Size, Trends and Insights By Type (Olaparib, Rucaparib,...
June 08, 2022 04:43 ET | Source: Research and Markets

Global PARP Inhibitors Cancer Therapy Market Outlook 2022-2028: PARP Inhibitors have Proved to be a Commercial Success in the Modern Cancer Therapeutic Segment

Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's...
June 27, 2019 08:30 ET | Source: Zenith Capital Corp.

Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer

CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the...
November 20, 2018 08:30 ET | Source: Zenith Capital Corp.

Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer

Collaboration to evaluate ZEN-3694 in combination with Talazoparib in TNBC patients; Phase 1b/2 trial expected to initiate 1Q 2019 CALGARY, Alberta, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Zenith...